ZYBERNO
Stock Report
Updated Sep 1, 2026

ABVC BioPharma, Inc. (ABVC)

Healthcare • NASDAQ

$0.86

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
8.0/100
POOR BUSINESS
ABVC BioPharma, Inc. (ABVC) scores 8/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-53.7%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.29x)
Operating Margin (Operational Efficiency):CRITICAL (-2,201.1%)
Return on Capital (Capital Efficiency):CRITICAL (-34.9%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

ABVC BioPharma, Inc. (ABVC) stock report — Zyberno Score 8/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:0.86
Market Cap:$22.35M

Valuation Multiples (3)

P/B Ratio:1.82x
P/S Ratio:75.49x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$24.08M

Price Action & Momentum (3)

Momentum Percentile:17 / 100
% of 52-Week High:25.2%
B. Profitability Assessment

Return Metrics (5)

ROA:-34.9%
Reinvestment Rate:-756.7%
Fundamental Growth Rate (g):264.1%

Margin Analysis (3)

Operating Margin Ttm:-2,201.1%
Net Margin Ttm:-2,400.9%
Ebitda Margin:-2,184.5%

TTM Performance (3)

Gross Margin Ttm:171.9%
Operating Margin Ttm:-2,201.1%
Net Margin Ttm:-2,400.9%

Yield Metrics (2)

Earnings Yield:-$32.19
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:73.5%
Latest Earnings Filed:2026-08-12

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):-36.5%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:0.07x
Quick Ratio:0.07x
Cash Ratio:0.01x

Leverage Analysis (3)

Debt To Equity Ttm:0.29x
Debt-to-Equity Ratio:0.29x
Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-46.07x
Times Interest Earned:-46.07

Capital Structure (4)

Working Capital:-5,282,776.00
Cash And Cash Equivalents:31,944.00
Long Term Debt:$1.41M
Net Debt:$1.73M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $296.00K
Linear Growth: -36.5%
📊 Click to view full ABVC Revenue analysis & methodology →
Cost Of Revenue Ttm:$763.00

Profitability Breakdown (2)

Gross profit TTM: $508.83K
Linear Growth: -17.9%
📊 Click to view full ABVC Gross Profit analysis & methodology →
-$6.52M

Bottom Line Performance (3)

-$7.11M
Income Before Tax:-$7.60M
Ebitda Ttm:-6,466,066.00

Operating Expenses (5)

Operating Expenses:6,515,269.00
R And D Expense:114,755.00
Sga Expense:2,837,669.00
Income Tax Expense:-$86.39K
Interest Expense:155,210.00

Expense Ratios (1)

Ebitda Margin:-2,184.5%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$19.40M
Current Assets:$411.73K
Ppe Net:12,831,939.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:7,131,155.00
Current Liabilities:5,694,505.00
Long Term Debt:$1.41M
Short Term Debt:$358.11K

Equity & Capital (3)

Equity:$12.27M
Retained Earnings:-$79.16M
Common Stock:100,000,000.00

Working Capital Items (3)

Accounts Receivable:1,529.00
Inventory:11,460.00
Accounts Payable:0.00

Special Items (2)

Contract Liabilities:12,600.00
Stock Based Compensation:253,041.00
C. Cash Flow Analysis

Operating Activities (2)

-$3.34M-$39.99M

Investment Activities (1)

Investing Cash Flow:$47.12K

Financing Activities (3)

Financing Cash Flow:-$342.18K
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$56.13K
Long Term Debt Repayments:$203.03K

Non-Cash Items (1)

Depreciation Amortization Ttm:49,203.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-0.29
-$0.29
Earnings Per Share Ttm:-$0.27

Revenue & Cash Per Share (2)

Sales Per Share Ttm:0.01
Operating Cash Flow Per Share:-$0.11

Book Value & Capital (2)

Book Value Per Share:$0.47
Cash Per Share:0.00

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.01x
Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:193.59x
Days Sales Outstanding Ttm:1.89

Inventory Management (2)

Inventory Turnover Ttm:0.07x
Days Inventory Outstanding Ttm:5,482.18

Payables & Cash Cycle (2)

Days Payable Outstanding:-999.00
Cash Conversion Cycle:6,483.06
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:60.00
Quality Score:30.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:-756.7%
Fundamental Growth Rate (g):264.1%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):-36.5%

Other Growth Rates (2)

Gross Profit Growth Rate (Linear):-17.9%
Book Value Growth Rate (Linear):23.4%
C. Company Profile & Context

Corporate Information (6)

Symbol:ABVC
Company Name:ABVC BioPharma, Inc.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:penny
Volume Category:N/A

Share Structure (3)

Shares Outstanding:26.06M
Shares Outstanding Basic:26.06M
Shares Outstanding Diluted:26.06M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-09-01 06:50:00 UTC
Data Timestamp:2026-08-20T18:13:40.059939
Scroll to Top